Company profile
REGENXBIO INC.
NASDAQ:RGNXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SURABGENE LOMPARVOVEC | phase3 | — | 5 | active |
| CLEMIDSOGENE LANPARVOVEC | phase2_3 | — | 2 | active |
| OMPENACLID | phase2_3 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02651675 | phase1_2 | terminated | 2016-03-01 | 2020-11-27 | REGENXBIO Inc. | A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) |
| NCT05693142 | phase2_3 | active_not_recruiting | 2023-01-04 | 2026-09-01 | REGENXBIO Inc. | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) |
| NCT03566043 | phase2_3 | active_not_recruiting | 2018-09-27 | 2023-11-27 | REGENXBIO Inc. | CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) |
| NCT03580083 | phase1_2 | suspended | 2019-04-03 | 2027-07-07 | REGENXBIO Inc. | RGX-111 Gene Therapy in Patients With MPS I |
| NCT04571970 | phase1_2 | completed | 2021-03-11 | 2023-05-09 | REGENXBIO Inc. | RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) |
FDA applications (0)
No records yet.